Epigenetic therapy of leukemia: An update
- 31 January 2009
- journal article
- review article
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 41 (1), 72-80
- https://doi.org/10.1016/j.biocel.2008.10.006
Abstract
No abstract availableKeywords
This publication has 93 references indexed in Scilit:
- MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivoMolecular Cancer Therapeutics, 2008
- The Epigenomics of CancerCell, 2007
- Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemiasBlood, 2006
- Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemiaBlood, 2006
- Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood, 2006
- Sequential Valproic Acid/All-trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid LeukemiaCancer Research, 2006
- Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitorBlood, 2006
- Histone Deacetylase Is a Target of Valproic Acid-Mediated Cellular DifferentiationCancer Research, 2004
- The SWI/SNF complex — chromatin and cancerNature Reviews Cancer, 2004
- Long-Term Treatment of Girls with Ornithine Transcarbamylase DeficiencyNew England Journal of Medicine, 1996